文献速递眼底病与葡萄膜炎

1型糖尿病视网膜病变预测模型的验证

Validation of a model for the prediction of retinopathy in persons with type 1 diabetes.
PubMed 文献 · Br J Ophthalmol · 2019-03-01

本研究在学术医院环境中回顾性验证了既往开发的1型糖尿病视网膜病变预测模型,用于个性化筛查。268例患者平均随访4.6年,24例(9.0%)发生威胁视力视网膜病变(STR),所有STR均发生在计算筛查日期之后。模型判别能力良好(Harrell's C-statistic=0.82,95%CI 0.74-0.90),校准显示高风险者风险被高估。结论提示基于该模型的筛查方案安全有效,可提高成本效益。

要点

  • 模型判别能力良好,Harrell's C-statistic=0.82(95%CI 0.74-0.90)。
  • 所有STR均发生在计算筛查日期之后,提示筛查间隔安全。
  • 平均计算筛查间隔30.5个月,较年度筛查减少61%,较两年筛查减少21%。

核心结论

  • 基于既往预测模型的筛查方案在1型糖尿病患者中安全有效,可改善糖尿病眼保健的成本效益。

研究设计与样本

  • 回顾性分析学术医院治疗的1型糖尿病患者医疗数据,验证既往开发的糖尿病视网膜病变预测模型。
  • 共纳入268例1型糖尿病患者,平均随访4.6年。

主要发现

  • 24例(9.0%)在平均4.6年随访期间发生威胁视力视网膜病变(STR)。
  • 所有STR发生均在计算筛查日期之后。
  • 模型判别能力良好,Harrell's C-statistic=0.82(95%CI 0.74-0.90)。
  • 校准显示被分配较高STR风险者的风险被高估。

关键数值与推荐

  • STR定义为存在重度非增殖性DR、增殖性DR或黄斑水肿。
  • 模型计算使用视网膜病变存在与分级、糖尿病发病、收缩压和血红蛋白A1c水平。
  • 平均计算筛查间隔为30.5个月,较年度筛查减少61%,较两年筛查减少21%。

临床怎么用

  • 可基于该模型计算个体化风险估计和个性化筛查间隔,替代固定年度筛查。
  • 高风险者风险可能被高估,临床应用时需注意校准。

局限性

  • 回顾性研究,数据来自学术医院环境,样本量268例,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIM: To validate a previously developed model for prediction of diabetic retinopathy (DR) for personalised retinopathy screening in persons with type 1 diabetes. METHODS: Retrospective medical data of persons with type 1 diabetes treated in an academic hospital setting were used for analysis. Sight-threatening retinopathy (STR) was defined as the presence of severe non-proliferative DR, proliferative DR or macular oedema. The presence and grade of retinopathy, onset of diabetes, systolic blood pressure, and levels of haemoglobin A1c were used to calculate an individual risk estimate and personalised screening interval. In persons with STR, the occurrence was compared with the calculated date of screening. The model's predictive performance was measured using calibration and discrimination techniques. RESULTS: Of the 268 persons included in our study, 24 (9.0%) developed STR during a mean follow-up of 4.6 years. All incidences of STR occurred after the calculated screening date. By applying the model, the mean calculated screening interval was 30.5 months, which is a reduction in screening frequency of 61% compared with annual screening and 21% compared with biennial screening. The discriminatory ability was good (Harrell's C-statistic=0.82, 95% CI 0.74 to 0.90), and calibration showed an overestimation of risk in persons who were assigned to a higher risk for STR. CONCLUSION: This validation study suggests that a screening programme based on the previously developed prediction model is safe and efficient. The use of a personalised screening frequency could improve cost-effectiveness of diabetic eye care.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Schreur V, Ng H, Nijpels G, et al. Validation of a model for the prediction of retinopathy in persons with type 1 diabetes. Br J Ophthalmol. 2019. PMID: 30824420. doi:10.1136/bjophthalmol-2018-313539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。